{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T04:28:26Z","timestamp":1786940906581,"version":"build-2736575974"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004606","name":"Chang Gung Medical Foundation","doi-asserted-by":"publisher","award":["CMRPG8P0631"],"award-info":[{"award-number":["CMRPG8P0631"]}],"id":[{"id":"10.13039\/501100004606","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Taiwan National Science and Technology Council","award":["112-2314-B-182-070-MY3"],"award-info":[{"award-number":["112-2314-B-182-070-MY3"]}]},{"name":"Taiwan National Science and Technology Council","award":["109-2314-B-182A-009-MY2"],"award-info":[{"award-number":["109-2314-B-182A-009-MY2"]}]},{"name":"Taiwan National Science and Technology Council","award":["111-2314-B-182A-027"],"award-info":[{"award-number":["111-2314-B-182A-027"]}]},{"name":"Taiwan National Science and Technology Council","award":["112-2314-B-182-070-MY3"],"award-info":[{"award-number":["112-2314-B-182-070-MY3"]}]},{"DOI":"10.13039\/501100004606","name":"Chang Gung Medical Foundation","doi-asserted-by":"publisher","award":["CMRPG8N0881"],"award-info":[{"award-number":["CMRPG8N0881"]}],"id":[{"id":"10.13039\/501100004606","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004606","name":"Chang Gung Medical Foundation","doi-asserted-by":"publisher","award":["CMRPG8P0631"],"award-info":[{"award-number":["CMRPG8P0631"]}],"id":[{"id":"10.13039\/501100004606","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004606","name":"Chang Gung Medical Foundation","doi-asserted-by":"publisher","award":["CORPG8P056,1"],"award-info":[{"award-number":["CORPG8P056,1"]}],"id":[{"id":"10.13039\/501100004606","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004606","name":"Chang Gung Medical Foundation","doi-asserted-by":"publisher","award":["BMRPJ30"],"award-info":[{"award-number":["BMRPJ30"]}],"id":[{"id":"10.13039\/501100004606","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Ulotaront is an experimental antipsychotic for schizophrenia, but its optimal dose is unclear. This study aimed to evaluate dose\u2013response relationships for efficacy and safety in people with schizophrenia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A systematic review of four databases (until January 22, 2025; INPLASY202510091) identified randomized clinical trials assessing ulotaront. Outcomes included efficacy, measured by changes in the Positive and Negative Syndrome Scale (PANSS) total score (primary outcome), positive and negative subdomains, and the Clinical Global Impression Scale-Severity, and safety, assessed by all-cause dropout (co-primary outcome, dropout due to adverse event, serious, non-serious, and specific adverse events). We employed one-stage dose\u2013response meta-analysis (random-effects model) calculating standardized mean differences (SMDs) and risk ratios (RRs) with 95% confidence intervals (CIs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Analysis of three randomized clinical trials (n\u2009=\u20091144) indicated that the 100\u00a0mg dose of ulotaront provided the greatest improvement in PANSS total score (standardized mean difference\u2009=\u2009\u22120.23 [95% CI: \u22120.43, \u22120.02]), PANSS positive symptom score (\u22120.30 [\u22120.70, 0.10]), and PANSS negative symptom score (\u22120.28 [\u22120.48, \u22120.08]). However, Clinical Global Impression Scale-Severity scores did not exhibit a clear dose\u2013response relationship. Regarding safety, all-cause dropout (RR at 100\u00a0mg\u2009=\u20091.10 [95% CI: 0.57, 2.12]), adverse event-related dropout, serious, non-serious, and most specific adverse events showed no significant dose\u2013response relationship. The risk of anxiety-related adverse events was significantly higher than placebo at 50 and 75\u00a0mg doses (RR at 75\u00a0mg\u2009=\u20092.06 [95% CI: 1.11, 3.80]).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Ulotaront 100\u00a0mg appears greatest efficacy with favorable safety for acute schizophrenia. However, effect sizes were small, and higher ulotaront doses should be tested.<\/jats:p>\n                  <jats:p>Significance Statement Ulotaront is a new medication being tested for treating schizophrenia. Unlike most existing antipsychotic drugs that block dopamine receptors in the brain, ulotaront works through a different mechanism by activating trace amine-associated receptor 1 and serotonin 1A receptors. These novel targets may help reduce both hallucinations and negative symptoms like social withdrawal and lack of motivation, with fewer side effects. In this study, we analyzed data from several clinical trials to understand how different doses of ulotaront affect patients. We found that higher doses\u2014especially around 100\u00a0mg\u2014can improve schizophrenia symptoms without increasing safety concerns. These findings are important because they suggest that ulotaront may offer a new and safer treatment option for people with schizophrenia, and they help guide doctors toward the most effective dose.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ijnp\/pyaf059","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T21:14:46Z","timestamp":1755033286000},"source":"Crossref","is-referenced-by-count":3,"title":["Trajectory of efficacy and safety across ulotaront dose levels in schizophrenia: a systematic review and dose\u2013response meta-analysis"],"prefix":"10.1093","volume":"28","author":[{"given":"Yu-Chia","family":"Hsu","sequence":"first","affiliation":[{"name":"Department of Medical Education, National Cheng Kung University Hospital and College of Medicine, National Cheng Kung University , Tainan ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Yen","family":"Hung","sequence":"additional","affiliation":[{"name":"Department of Medical Education, National Cheng Kung University Hospital and College of Medicine, National Cheng Kung University , Tainan ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang-Chieh Brian","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, The University of Texas Health Science Center at Houston , Houston, TX ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Chuan","family":"Hung","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Chi Mei Medical Center , Tainan ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1138-5586","authenticated-orcid":false,"given":"Chih-Sung","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Beitou Branch, Tri-Service General Hospital, National Defense Medical University , Taipei ,","place":["Taiwan"]},{"name":"Department of Psychiatry, National Defense Medical University , Taipei ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5761-7800","authenticated-orcid":false,"given":"Ping-Tao","family":"Tseng","sequence":"additional","affiliation":[{"name":"Prospect Clinic for Otorhinolaryngology & Neurology , Kaohsiung ,","place":["Taiwan"]},{"name":"Institute of Biomedical Sciences, National Sun Yat-sen University , Kaohsiung ,","place":["Taiwan"]},{"name":"Department of Psychology, College of Medical and Health Science, Asia University , Taichung ,","place":["Taiwan"]},{"name":"Institute of Precision Medicine, National Sun Yat-sen University , Kaohsiung City ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2461-474X","authenticated-orcid":false,"given":"Yu-Kang","family":"Tu","sequence":"additional","affiliation":[{"name":"Institute of Health Data Analytics & Statistics, College of Public Health, National Taiwan University , Taipei ,","place":["Taiwan"]},{"name":"Health Data Research Center, National Taiwan University , Taipei ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph U","family":"Correll","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, Charit\u00e9 Universit\u00e4tsmedizin , Berlin ,","place":["Germany"]},{"name":"Department of Psychiatry, Zucker Hillside Hospital, Northwell Health , Glen Oaks ,","place":["United States"]},{"name":"Department of Psychiatry and Molecular Medicine, Zucker School of Medicine at Hofstra\/Northwell , Hempstead ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8650-4060","authenticated-orcid":false,"given":"Chih-Wei","family":"Hsu","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine , Kaohsiung ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Solmi","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, Charit\u00e9 Universit\u00e4tsmedizin , Berlin ,","place":["Germany"]},{"name":"Department of Psychiatry, University of Ottawa , Ottawa ,","place":["Canada"]},{"name":"Department of Mental Health, The Ottawa Hospital , Ottawa ,","place":["Canada"]},{"name":"Ottawa Hospital Research Institute , Ottawa ,","place":["Canada"]},{"name":"School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa , Ottawa ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,8]]},"reference":[{"key":"2025091010214105700_ref1","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1056\/NEJMra1808803","article-title":"Schizophrenia","volume":"381","author":"Marder","year":"2019","journal-title":"N Engl J Med"},{"key":"2025091010214105700_ref2","doi-asserted-by":"publisher","first-page":"S165","DOI":"10.1093\/schbul\/sbu006","article-title":"Schizophrenia\u2014time to commit to policy change","volume":"40","author":"Fleischhacker","year":"2014","journal-title":"Schizophr Bull"},{"key":"2025091010214105700_ref3","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1093\/schbul\/sbp006","article-title":"The dopamine hypothesis of schizophrenia: version III--the final common pathway","volume":"35","author":"Howes","year":"2009","journal-title":"Schizophr Bull"},{"key":"2025091010214105700_ref4","doi-asserted-by":"publisher","first-page":"448","DOI":"10.47626\/1516-4446-2023-3126","article-title":"Treatment resistance in schizophrenia: a meta-analysis of prevalence and correlates","volume":"45","author":"Diniz","year":"2023","journal-title":"Braz J Psychiatry"},{"key":"2025091010214105700_ref5","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.18com12123","article-title":"Clinical guidance on the identification and management of treatment-resistant schizophrenia","volume":"80","author":"Kane","year":"2019","journal-title":"J Clin Psychiatry"},{"key":"2025091010214105700_ref6","doi-asserted-by":"publisher","first-page":"280","DOI":"10.4088\/JCP.08m04250yel","article-title":"Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study","volume":"71","author":"Bobes","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"2025091010214105700_ref7","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2147\/ndt.S225643","article-title":"Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment","volume":"16","author":"Correll","year":"2020","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2025091010214105700_ref8","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/nrd3628","article-title":"Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy","volume":"11","author":"Millan","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"2025091010214105700_ref9","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2147\/tcrm.S117321","article-title":"Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review","volume":"13","author":"Solmi","year":"2017","journal-title":"Ther Clin Risk Manag"},{"key":"2025091010214105700_ref10","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/s2215-0366(23)00262-6","article-title":"Antidepressant and antipsychotic side-effects and personalised prescribing: a systematic review and digital tool development","volume":"10","author":"Pillinger","year":"2023","journal-title":"Lancet Psychiatry"},{"key":"2025091010214105700_ref11","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1176\/appi.ajp.2020.177901","article-title":"The American Psychiatric Association Practice Guideline for the treatment of patients with schizophrenia","volume":"177","author":"Keepers","year":"2020","journal-title":"Am J Psych"},{"key":"2025091010214105700_ref12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4088\/JCP.10075su1.02","article-title":"What are we looking for in new antipsychotics?","volume":"72","author":"Correll","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"2025091010214105700_ref13","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.Su21024ip1","article-title":"Emerging treatments in schizophrenia","volume":"83","author":"Correll","year":"2022","journal-title":"J Clin Psychiatry."},{"key":"2025091010214105700_ref14","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.euroneuro.2024.11.013","article-title":"Efficacy, tolerability, and safety of xanomeline-trospium chloride for schizophrenia: a systematic review and meta-analysis","volume":"92","author":"Fabiano","year":"2024","journal-title":"Eur Neuropsychopharmacol"},{"key":"2025091010214105700_ref15","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/wps.21056","article-title":"The future of psychopharmacology: a critical appraisal of ongoing phase 2\/3 trials, and of some current trends aiming to de-risk trial programmes of novel agents","volume":"22","author":"Correll","year":"2023","journal-title":"World Psychiatry"},{"key":"2025091010214105700_ref16","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1080\/13543784.2022.2158811","article-title":"Ulotaront: a TAAR1\/5-HT1A agonist in clinical development for the treatment of schizophrenia","volume":"31","author":"H\u00f8jlund","year":"2022","journal-title":"Expert Opin Investig Drugs"},{"key":"2025091010214105700_ref17","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s00406-023-01580-3","article-title":"Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia","volume":"273","author":"Achtyes","year":"2023","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"2025091010214105700_ref18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/jpet.119.260281","article-title":"SEP-363856, a novel psychotropic agent with a unique, non-D(2) receptor mechanism of action","volume":"371","author":"Dedic","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"2025091010214105700_ref19","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1056\/NEJMoa1911772","article-title":"A non-D2-receptor-binding drug for the treatment of schizophrenia","volume":"382","author":"Koblan","year":"2020","journal-title":"N Engl J Med"},{"key":"2025091010214105700_ref20","article-title":"A randomized, double-blind, parallel-group, placebo-controlled, fixed dose, Multicenter study to evaluate the efficacy and safety of SEP363856 in acutely psychotic subjects with schizophrenia","year":"2023","journal-title":"EU Clin Trials Register"},{"key":"2025091010214105700_ref21","doi-asserted-by":"publisher","DOI":"10.12688\/wellcomeopenres.21302.1","article-title":"Trace amine-associated receptor 1 (TAAR1) agonism for psychosis: a living systematic review and meta-analysis of human and non-human data [version 1; peer review: 3 approved]","volume":"9","author":"Siafis","year":"2024","journal-title":"Wellcome Open Res"},{"key":"2025091010214105700_ref22","doi-asserted-by":"publisher","first-page":"102308","DOI":"10.1016\/j.eclinm.2023.102308","article-title":"Efficacy and safety of zuranolone in major depressive disorder: a meta-analysis of factor effect and dose-response analyses","volume":"66","author":"Lin","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2025091010214105700_ref23","doi-asserted-by":"publisher","first-page":"e2445885","DOI":"10.1001\/jamanetworkopen.2024.45885","article-title":"Response trajectories and temporal trends of viloxazine treatment for young people with ADHD: a meta-analysis","volume":"7","author":"Yu","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2025091010214105700_ref24","doi-asserted-by":"publisher","DOI":"10.1136\/bmjment-2024-301165","article-title":"Efficacy and acceptability of lurasidone for bipolar depression: a systematic review and dose-response meta-analysis","volume":"27","author":"Lin","year":"2024","journal-title":"BMJ Ment Health"},{"key":"2025091010214105700_ref25","doi-asserted-by":"publisher","first-page":"e1230","DOI":"10.1002\/cl2.1230","article-title":"PRISMA2020: an R package and shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and open synthesis","volume":"18","author":"Haddaway","year":"2022","journal-title":"Campbell Syst Rev"},{"key":"2025091010214105700_ref26","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2025091010214105700_ref27","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1177\/1536867X0600600103","article-title":"Generalized least squares for trend estimation of summarized dose\u2013response data","volume":"6","author":"Orsini","year":"2006","journal-title":"Stata J"},{"key":"2025091010214105700_ref28","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/sim.3841","article-title":"Dose-response analyses using restricted cubic spline functions in public health research","volume":"29","author":"Desquilbet","year":"2010","journal-title":"Stat Med"},{"key":"2025091010214105700_ref29","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1302\/2046-3758.49.2000571","article-title":"Interpreting regression models in clinical outcome studies","volume":"4","author":"Hamilton","year":"2015","journal-title":"Bone Joint Res"},{"key":"2025091010214105700_ref30","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1177\/0962280218773122","article-title":"One-stage dose-response meta-analysis for aggregated data","volume":"28","author":"Crippa","year":"2019","journal-title":"Stat Methods Med Res"},{"key":"2025091010214105700_ref31","volume-title":"A Phase 2\/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Flexible Doses of SEP-363856 as Adjunctive Therapy in the Treatment of Adults with Major Depressive Disorder"},{"key":"2025091010214105700_ref32","volume-title":"A Phase 2\/3, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Flexible-Dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder"},{"key":"2025091010214105700_ref33","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/mp.2012.57","article-title":"A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight","volume":"18","author":"Revel","year":"2013","journal-title":"Mol Psychiatry"},{"key":"2025091010214105700_ref34","doi-asserted-by":"publisher","first-page":"8485","DOI":"10.1073\/pnas.1103029108","article-title":"TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity","volume":"108","author":"Revel","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"2025091010214105700_ref35","doi-asserted-by":"publisher","DOI":"10.1038\/s41537-023-00385-6","article-title":"Effects of ulotaront on brain circuits of reward, working memory, and emotion processing in healthy volunteers with high or low schizotypy","volume":"9","author":"Perini","year":"2023","journal-title":"Schizophrenia"},{"key":"2025091010214105700_ref36","volume-title":"An Open-Label Positron Emission Tomography Study to Investigate the Effect of Adjunctive Administration of SEP-363856 on Brain Dopamine Synthesis Capacity Using 18F-DOPA in Adult Subjects with Schizophrenia"},{"key":"2025091010214105700_ref37","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11071977","article-title":"Unlocking the therapeutic potential of ulotaront as a trace amine-associated receptor 1 agonist for neuropsychiatric disorders","volume":"11","author":"Kuvarzin","year":"2023","journal-title":"Biomedicines."},{"key":"2025091010214105700_ref38","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1111\/pcn.13592","article-title":"Placebo effects on all-cause mortality of patients with COVID-19 in randomized controlled trials of interleukin 6 antagonists: a systematic review and network meta-analysis","volume":"77","author":"Tseng","year":"2023","journal-title":"Psychiatry Clin Neurosci"},{"key":"2025091010214105700_ref39","doi-asserted-by":"publisher","first-page":"113069","DOI":"10.1016\/j.psychres.2020.113069","article-title":"COVID-19 pandemic: impact on psychiatric care in the United States","volume":"289","author":"Bojdani","year":"2020","journal-title":"Psychiatry Res"},{"key":"2025091010214105700_ref40","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/s41386-019-0547-9","article-title":"Safety and effectiveness of SEP-363856 in schizophrenia: results of a 6-month, open-label extension study","volume":"44","author":"Correll","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"2025091010214105700_ref41","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1192\/bjp.bp.108.053124","article-title":"Social anxiety disorder in first-episode psychosis: incidence, phenomenology and relationship with paranoia","volume":"195","author":"Michail","year":"2009","journal-title":"Br J Psychiatry"},{"key":"2025091010214105700_ref42","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/da.10083","article-title":"Prevalence and relationship to delusions and hallucinations of anxiety disorders in schizophrenia","volume":"17","author":"Tibbo","year":"2003","journal-title":"Depress Anxiety"},{"key":"2025091010214105700_ref43","doi-asserted-by":"publisher","first-page":"747","DOI":"10.4088\/jcp.v60n1105","article-title":"Depressive and anxiety symptoms in patients with schizophrenia and schizophreniform disorder","volume":"60","author":"Emsley","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"2025091010214105700_ref44","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.psychres.2013.05.013","article-title":"Psychiatric comorbidity among adults with schizophrenia: a latent class analysis","volume":"210","author":"Tsai","year":"2013","journal-title":"Psychiatry Res"}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyaf059\/63990183\/pyaf059.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/28\/9\/pyaf059\/63990183\/pyaf059.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/28\/9\/pyaf059\/63990183\/pyaf059.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T14:21:50Z","timestamp":1757514110000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/doi\/10.1093\/ijnp\/pyaf059\/8228252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,8]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyaf059","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,8,8]]},"article-number":"pyaf059"}}